Crescent Biopharma holder to sell $15K in shares

Jonathan McNeill filed a Rule 144 notice to resell 804 CBIO ordinary shares on or after September 16, 2026, following recent RSU vesting and prior sales.

Rhea-AI Filing Summary

CRESCENT BIOPHARMA, INC. (CBIO) is the issuer for a planned resale of its ordinary shares under Rule 144 by Jonathan McNeill. The notice lists a proposed sale of 804 ordinary shares, with an aggregate market value of $15,115.20, on or after September 16, 2026, on Nasdaq. McNeill previously acquired 1,595 shares through restricted stock unit vesting on September 15, 2026 and sold 20,549 shares for $369,768.98 on June 22, 2026.

Key Figures

Shares proposed to be sold: 804 shares Aggregate market value of proposed sale: $15,115.20 Shares outstanding: 37,143,940 shares +3 more

6 metrics

Shares proposed to be sold 804 shares Ordinary shares to be sold under Rule 144 on or after September 16, 2026

Aggregate market value of proposed sale $15,115.20 Value of 804 ordinary shares listed in the Rule 144 notice

Shares outstanding 37,143,940 shares Ordinary shares outstanding for Crescent Biopharma, Inc. referenced in the notice

Recent shares acquired 1,595 shares Ordinary shares acquired via Restricted Stock Unit Vesting on September 15, 2026

Shares sold in past 3 months 20,549 shares Ordinary shares sold by Jonathan McNeill on June 22, 2026

Proceeds from prior sale $369,768.98 Total consideration for 20,549 ordinary shares sold on June 22, 2026

Key Terms

Rule 144, Restricted Stock Unit Vesting, Attorney-in-Fact, Power of Attorney

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Unit Vesting financial

"Ordinary Shares | 09/15/2026 | Restricted Stock Unit Vesting | Issuer"

Attorney-in-Fact regulatory

"Signature | /s/ Barbara Bispham Hale, as Attorney-in-Fact for Jonathan McNeill"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

Power of Attorney regulatory

"Remarks | Exhibit List - Exhibit 24 - Power of Attorney"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for CRESCENT BIOPHARMA, INC. (CBIO)?

It discloses that Jonathan McNeill filed a Rule 144 notice to sell 804 ordinary shares of CBIO, valued at $15,115.20, on or after September 16, 2026 on Nasdaq.

How many CBIO shares is Jonathan McNeill proposing to sell under this Form 144?

The notice lists a proposed sale of 804 ordinary shares of CRESCENT BIOPHARMA, INC., with an aggregate market value of $15,115.20, to be sold on or after September 16, 2026.

What recent CBIO share acquisitions are reported for Jonathan McNeill?

The filing reports that Jonathan McNeill acquired 1,595 ordinary shares of CBIO on September 15, 2026 through Restricted Stock Unit Vesting from the issuer for services rendered.

What CBIO share sales has Jonathan McNeill made in the past three months?

The Form 144 states that on June 22, 2026, Jonathan McNeill sold 20,549 ordinary shares of CBIO for total proceeds of $369,768.98.

How many Crescent Biopharma (CBIO) shares are outstanding as noted in this filing?

The securities information section notes 37,143,940 ordinary shares of CRESCENT BIOPHARMA, INC. outstanding in connection with the Form 144 notice.

Who signed the Form 144 related to CBIO on behalf of Jonathan McNeill?

The notice is signed by /s/ Barbara Bispham Hale, as Attorney-in-Fact for Jonathan McNeill, referencing an Exhibit 24 Power of Attorney.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/16/2026 - 03:09 PM Accepted by SEC EDGAR 09/16/2026 - 03:09 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001824673
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Crescent Biopharma, Inc.
SEC File Number	001-36177
Address of Issuer	300 5th Ave Waltham MASSACHUSETTS 02451
Phone	6174305595
Name of Person for Whose Account the Securities are To Be Sold	Jonathan McNeill
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Ordinary Shares	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	804	15115.2	37143940	09/16/2026	Nasdaq

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Ordinary Shares	09/15/2026	Restricted Stock Unit Vesting	Issuer			1595	09/15/2026	Services rendered

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Jonathan McNeill 300 5th Ave Waltham MA 02451	Ordinary Shares	06/22/2026	20549	369768.98

144: Remarks and Signature

Remarks	Exhibit List - Exhibit 24 - Power of Attorney
Date of Notice	09/16/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/25/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Barbara Bispham Hale, as Attorney-in-Fact for Jonathan McNeill
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)